A DNA vaccine can slow disease progression and prolong survival in a mouse model of leukemia, according to a report in the November issue of Nature Medicine.
Rose Ann Padua and coworkers developed a vaccine with pieces of DNA encoding PML-RAR-alpha, a tumor-associated protein, and fragment C of tetanus toxin, a potent immune system stimulant. When injected into a mouse model of acute promyelocytic leukemia (APL), a rare cancer of the white blood cells, the vaccine induced the immune system to make antibodies against the PML-RAR-alpha protein, which is commonly found in APL cancer cells.
The vaccine was even more effective at increasing survival when used in combination with all-trans retinoic acid (ATRA), a drug currently used to treat APL. The vaccine-ATRA duo was even more effective than ATRA alone. The researchers suggest the vaccine could eventually be used with ATRA to prolong clinical remission in human patients.
Rose Ann Padua
King's College Hospital
Tel: +44 20 7848 5825
Also available online.
(C) Nature Medicine press release.
Message posted by: Trevor M. D'Souza